Literature DB >> 31059420

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.

Mark Warren1,2, Michael Kolinsky1,3, Christina M Canil4,5, Piotr Czaykowski6,7, Srikala S Sridhar8, Peter C Black9, Christopher M Booth10, Wassim Kassouf11, Libni Eapen12,5, Som D Mukherjee13, Normand Blais14, Bernhard J Eigl15, Eric Winquist16, Naveen S Basappa1,3, Scott A North1,3.   

Abstract

Entities:  

Year:  2019        PMID: 31059420      PMCID: PMC6788915          DOI: 10.5489/cuaj.6015

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  63 in total

1.  Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.

Authors:  Matthew D Galsky; Alexia Iasonos; Svetlana Mironov; Joseph Scattergood; Mary G Boyle; Dean F Bajorin
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

Review 2.  Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.

Authors:  Vincenzo Di Nunno; Emmanuele De Luca; Consuelo Buttigliero; Marcello Tucci; Francesca Vignani; Lidia Gatto; Clizia Zichi; Andrea Ardizzoni; Massimo Di Maio; Francesco Massari
Journal:  Crit Rev Oncol Hematol       Date:  2018-07-19       Impact factor: 6.312

3.  Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

Authors:  J A McCaffrey; S Hilton; M Mazumdar; S Sadan; W K Kelly; H I Scher; D F Bajorin
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

4.  Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.

Authors:  Tom J N Hermans; Elisabeth E Fransen van de Putte; Simon Horenblas; Richard P Meijer; Joost L Boormans; Katja K H Aben; Michiel S van der Heijden; Ronald de Wit; Laurens V Beerepoot; Rob H A Verhoeven; Bas W G van Rhijn
Journal:  Eur J Cancer       Date:  2016-10-27       Impact factor: 9.162

5.  Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.

Authors:  Anne Birgitte Als; Lisa Sengelov; Hans von der Maase
Journal:  Eur Urol       Date:  2007-03-15       Impact factor: 20.096

6.  Induction chemotherapy for unresectable urothelial carcinoma of the bladder.

Authors:  Pirus Ghadjar; Fiona C Burkhard; Oliver Gautschi; George N Thalmann; Urs E Studer
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

7.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

8.  Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.

Authors:  Fabio Calabrò; Vito Lorusso; Gerardo Rosati; Luigi Manzione; Luca Frassineti; Teodoro Sava; Eugenio Donato Di Paula; Silvia Alonso; Cora N Sternberg
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

9.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Authors:  Christophe Massard; Michael S Gordon; Sunil Sharma; Saeed Rafii; Zev A Wainberg; Jason Luke; Tyler J Curiel; Gerardo Colon-Otero; Omid Hamid; Rachel E Sanborn; Peter H O'Donnell; Alexandra Drakaki; Winston Tan; John F Kurland; Marlon C Rebelatto; Xiaoping Jin; John A Blake-Haskins; Ashok Gupta; Neil H Segal
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

10.  A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.

Authors:  Barbara J Gitlitz; Carole Baker; Yvonne Chapman; Heather J Allen; Linda D Bosserman; Ravi Patel; James D Sanchez; Richard M Shapiro; Robert A Figlin
Journal:  Cancer       Date:  2003-11-01       Impact factor: 6.860

View more
  2 in total

1.  Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.

Authors:  Thomas Powles; Jonathan E Rosenberg; Guru P Sonpavde; Yohann Loriot; Ignacio Durán; Jae-Lyun Lee; Nobuaki Matsubara; Christof Vulsteke; Daniel Castellano; Chunzhang Wu; Mary Campbell; Maria Matsangou; Daniel P Petrylak
Journal:  N Engl J Med       Date:  2021-02-12       Impact factor: 91.245

2.  Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancer.

Authors:  Tarik Benidir; Jaime Herrera-Caceres; Christopher Wallis; Katherine Lajkosz; Neil Fleshner
Journal:  Cancer Med       Date:  2021-03-12       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.